In the past decade, nucleic-acid-based drugs have become firmly established as a therapeutic modality. Drugs in two classes have now reached the market for multiple diseases—antisense oligonucleotides ...
As the global small nucleic acid drugs market rapidly expands, driven by growing demand for precise treatments targeting genetic disorders, rare diseases, and cancer. The high specificity of small ...
Harnessing surface engineering strategies to functionalize nucleic acid-lipid nanoparticles (LNPs) for improved performance has been a hot research topic since the approval of the first siRNA drug, ...
BOSTON--(BUSINESS WIRE)--Alloy Therapeutics, a biotechnology ecosystem company, announced the launch of its novel AntiClastic™ Antisense Oligonucleotide (AntiClastic ASO) platform, which employs ...
Anti-nucleolin DNA aptamer, iSN04, inhibits angiogenesis. Mouse aortic rings embedded in collagen gel were cultured with or without 30 µM iSN04 for 6 days. Neovascular sprouting, a model of ...
Nucleic acids are complex biological molecules that store and transmit genetic information in all living organisms. They are essential for the survival and reproduction of life on Earth. The two main ...
Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback